

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/561,711
	Filing Date	September 11, 2009
	First Named Inventor	William H. Fenical
	Art Unit	1626
(Multiple sheets used when necessary)	Examiner	Powers, Fiona
SHEET 1 OF 21	Attorney Docket No.	UCSD1530-5

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	5,445,829	8-29-1995	Paradissis, et al.	
	2	5,576,012	11-19-1996	Bauer, et al.	
	3	5,601,845	2-11-1997	Buxton, et al.	
	4	5,641,515	6-24-1997	Ramtoola	
	5	5,653,987	8-5-1997	Modi, et al.	
	6	5,654,286	8-5-1997	Hostetler	
	7	5,667,809	9-16-1997	Trevino, et al.	
	8	5,683,676	11-4-1997	Akehurst, et al.	
	9	5,688,529	11-18-1997	Lidgate, et al.	
	10	5,707,615	1-13-1998	Cardin, et al.	
	11	5,707,641	1-13-1998	Gertner, et al.	
	12	5,726,181	3-10-1998	Hausheer, et al.	
	13	5,733,888	3-31-1998	Carver, et al.	
	14	5,756,764	5-26-1998	Fenteany, et al.	
	15	5,874,443	2-23-1999	Kiely, et al.	
	16	5,886,210	3-23-1999	Rayle, et al.	
	17	5,922,683	7-13-1999	Or, et al.	
	18	6,133,308	10-17-2000	Soucy, et al.	
	19	6,147,223	11-14-2000	Fenteany, et al.	
	20	6,214,862	4-10-2001	Fenteany, et al.	
	21	6,271,199	8-7-2001	Brand, et al.	
	22	6,294,560	9-25-2001	Soucy, et al.	
	23	6,333,358	12-25-2001	Nakazato, et al.	
	24	6,335,358	1-1-2002	Fenteany, et al.	
	25	6,350,759	2-26-2002	Casara, et al.	
	26	6,458,825	10-1-2002	Fenteany, et al.	
	27	6,500,825	12-31-2002	Lan, et al.	

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
<p>WEST\223652834.1 328342-000349</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/561,711
	Filing Date	September 11, 2009
	First Named Inventor	William H. Fenical
	Art Unit	1626
(Multiple sheets used when necessary)	Examiner	Powers, Fiona
SHEET 2 OF 21	Attorney Docket No.	UCSD1530-5

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	28	6,506,787	1-14-2003	Fujishita, et al.	
	29	6,509,331	1-21-2003	Audia, et al.	
	30	6,566,553	5-20-2003	Soucy, et al.	
	31	6,645,999	11-11-2003	Schreiber, et al.	
	32	6,794,516	9-21-2004	Soucy, et al.	
	33	6,838,477	1-4-2005	Schreiber, et al.	
	34	6,849,743	2-1-2005	Soucy, et al.	
	35	7,144,723	12-5-2006	Fenical, et al.	
	36	7,176,232	2-13-2007	Fenical, et al.	
	37	7,176,233	2-13-2007	Fenical, et al.	
	38	7,179,834	2-20-2007	Fenical et al.	
	39	7,183,417	2-27-2007	Corey, Elias J.	
	40	7,276,530	10-2-2007	Potts, et al.	
	41	7,371,875	5-13-2008	Xiao, et al.	
	42	7,511,156	03-31-2009	Corey	
	43	7,544,814	6-09-2009	Potts, et al.	
	44	7,572,606	8-11-2009	Lam, et al.	
	45	7,579,371	8-25-2009	Palladino, et al.	
	46	7,635,712	12-22-09	Fenical, et al.	
	47	7,879,576	02-01-2001	Fenical, et al.	
	48	7,910,616	03-22-2011	Macherla, et al.	
	49	7,928,138	12-28-2007	Fenical, et al.	
	50	2001/0002391	5-31-2001	Brand, et al.	
	51	2001/0051654	12-13-2001	Elliott, et al.	
	52	2003/0157695	8-21-2003	Fenical, et al.	
	53	2004/0138196	7-15-2004	Fenical, et al.	
	54	2005/0049294	3-3-2005	Palladino, et al.	

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>WEST223652834.1 328342-000349</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/561,711
	Filing Date	September 11, 2009
	First Named Inventor	William H. Fenical
	Art Unit	1626
(Multiple sheets used when necessary)	Examiner	Powers, Fiona
SHEET 3 OF 21	Attorney Docket No.	UCSD1530-5

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	55	2005/0203029	9-15-2005	Schubert, et al.	
	56	2005/0203162	9-15-2005	Xiao, et al.	
	57	2005/0239866	2-13-2007	Fenical, et al.	
	58	2006/0008852	1-12-2006	Fenical, et al.	
	59	2006/0229353	10-12-2006	Stadler, et al.	
	60	2006/0264495	11-23-2006	Palladino, et al.	
	61	2006/0287520	12-21-2006	Danishefsky, et al.	
	62	2007/0004676	1-4-2007	Palladino, et al.	
	63	2007/0155815	7-5-2007	Fenical, et al.	
	64	2007/0161693	7-12-2007	Corey, Elias J.	
	65	2007/0225350	9-27-2007	Anderson, et al.	
	66	2008/0070273	3-20-2008	Fenical, et al.	
	67	2008/0070969	3-20-2008	Potts, et al.	
	68	2008/0280968	11-13-2008	Palladino, et al.	
	69	2009/0036390	02-05-2009	Anderson, et al.	
	70	2009/0062547	3-5-2009	Romo, et al.	
	71	2009/0069401	3-12-2009	Fenical, et al.	
	72	2009/0148445	6/11/2009	Bonavida, et al.	
	73	2009/0156469	06-18-2009	Ghobrial, et al.	
	74	2009/0197937	8-6-2009	Fenical, et al.	
	75	2009/0298906	12-3-2009	Macherla, et al.	
	76	2009/0318529	12-24-2009	Fenical, et al.	
	77	2010/0144826	6-10-2010	Fenical, et al.	
	78	2010/0168046	7-1-2010	Palladino, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
<p>WEST\223652834.1 328342-000349</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/561,711
	Filing Date	September 11, 2009
	First Named Inventor	William H. Fenical
	Art Unit	1626
(Multiple sheets used when necessary)		Examiner
SHEET 4 OF 21		Powers, Fiona
		Attorney Docket No.
		UCSD1530-5

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	79	CA 2429163	6-20-2002	The Regents of the University of California		
	80	WO 1996/032105	10-17-1996	President and Fellows of Harvard College		
	81	WO 1998/035691	08-20-1998	Proscript, Inc.		
	82	WO 1999/009006	2-25-1999	Soucy et al.		
	83	WO 1999/015183	4-1-1999	Proscript		
	84	WO 2000/023614	4-27-2000	Leukosite, Inc.		
	85	WO 2002/047610	6-20-2002	The Regents of the University of California		
	86	WO 2004/043374	5-27-2004	Dana-Farber Cancer Institute Inc.		
	87	WO 2004/071382	8-26-2004	Bayer Healthcare AG		
	88	WO 2005/002572	1-13-2005	Nereus Pharmaceuticals, Inc.		
	89	WO 2005/003137	1-13-2005	The Regents of the University of California		
	90	WO 2005/094423	10-13-2005	President and Fellows of Harvard College		
	91	WO 2005/099687	10-27-2005	President and Fellows of Harvard College		
	92	WO 2006/005551	1-19-2006	BAYER Cropscience AG		
	93	WO 2006/028525	3-16-2005	Nereus Pharmaceuticals, Inc.		
	94	WO 2006/060609	6-8-2006	Honeywell Int., Inc.		
	95	WO 2006/060676	6-8-2006	Dana-Farber Cancer Institute Inc.		
	96	WO 2006/060809	6-8-2006	Nereus Pharmaceuticals, Inc.		
	97	WO 2006/118973	11-9-2006	Nereus Pharmaceuticals, Inc.		
	98	WO 2007/021897	2-22-2007	President and Fellows of Harvard College		
	99	WO 2007/033039	3-22-2007	President and Fellows of Harvard College		
	100	WO 2007/130404	11-15-2007	Nereus Pharmaceuticals		
	101	WO 2007/138116	12-6-2007	Virologik GmbH		

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>WEST\223652834.1 328342-000349</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

PTO/SB/08 Equivalent

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/561,711
	Filing Date	September 11, 2009
	First Named Inventor	William H. Fenical
	Art Unit	1626
(Multiple sheets used when necessary)	Examiner	Powers, Fiona
SHEET 5 OF 21	Attorney Docket No.	UCSD1530-5

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	102	WO 2008/124699	10-16-2008	Nereus Pharmaceuticals, Inc.		
	103	WO 2008/137780	11-13-2008	Nereus Pharmaceuticals, Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	104	ADAMS, et al., "Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents," <i>Cancer Res.</i> , (1999) 59:2615-2622.	
	105	ADAMS, J., "The Development of Novel Targeted Therapeutics for Treatment of Multiple Myeloma Research Roundtable," <i>Euro. J. Haematology</i> , (2003) 70:265.	
	106	ADAMS, J., "Proteasome Inhibitors as New Anticancer Drugs," <i>Curr. Opin. Oncol.</i> , (2002) 14:628-34.	
	107	ALESSANDRI, et al., "Mobilization of Capillary Endothelium In Vitro Induced by Effectors of Angiogenesis In Vivo," <i>Cancer Res.</i> , (1983) 43(4):1790-1797.	
	108	ALM, et al., "Effects of Topically Applied PGF2 and its Isopropylester on Normal and Glaucomatous Human Eyes," <i>Prog. Clin. Biol. Res.</i> , (1989) 312:447-58.	
	109	ANDTBACKA, et al., "The proteasome inhibitor NPI-0052 overcomes TRAIL resistance in human pancreatic cancer cells in vitro and in vivo," (unpublished manuscript).	
	110	ANDTBACKA, et al., "The Proteasome Inhibitor NPI-0052 Sensitizes Pancreatic Cancer Cells to TRAIL In Vitro and In Vivo," <i>Amer. Assoc. Cancer Res.</i> , (2005) 46: Abstract #1721.	
	111	BARRAL, et al., "The Proteasome Inhibitor NPI-0052 Reduces Tumor Growth and Overcomes Resistance of Prostate Cancer to rhTRAIL via Inhibition of the NF-kB Pathway," <i>Amer. Assoc. Cancer Res.</i> , (2007): abstract 1465.	
	112	BEERS, et al., (Eds.), "Bacterial Diseases," <i>The Merck Manual of Diagnosis and Therapy</i> , (1999) The Merck Research Laboratories, Whitehouse Station N.J., Section 13, Chapter 157: pp. 1157-1158.	
	113	BEERS, et al., (Eds.), "Parasitic Infections," <i>The Merck Manual of Diagnosis and Therapy</i> , (1999) The Merck Research Laboratories, Whitehouse Station N.J., Section 13, Chapter 161: pp. 1241-1252.	
	114	BEERS, et al., (Eds.), <i>The Merck Manual of Diagnosis and Therapy</i> , 17th Ed. 1999, The Merck Research Laboratories, Whitehouse Station N.J., pp. 397-399, 948-949, 1916-1917, 1974-1975 and 1978-1983.	
	115	BEERS, et al., (Eds.), <i>The Merck Manual of Diagnosis and Therapy</i> , 17th Ed. 1999, The Merck Research Laboratories, Whitehouse Station N.J., pp. 1193-1201 & 1204.	
	116	BEERS, et al., (Eds.), "The Merck Manual of Diagnosis and Therapy", 17th Ed. 1999, The Merck Research Laboratories, Whitehouse Station N.J., pp. 1085-1088, 1101-1135, and 1237-1276.	

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>WEST\223652834.1 328342-000349</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 6 OF 21

Application No.	10/561,711
Filing Date	September 11, 2009
First Named Inventor	William H. Fenical
Art Unit	1626
Examiner	Powers, Fiona
Attorney Docket No.	UCSD1530-5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	117	BERNAN, et al., "Marine Microorganisms as a Source of New Natural Products," <i>Advances in Applied Microbiology</i> , (1997) 43:57-90.	
	118	BHALLA, et al., "High-Dose Mitoxantrone Induces Programmed Cell Death or Apoptosis in Human Myeloid Leukemia Cells," <i>Blood</i> , (1993) 82(10):3133-3140.	
	119	BICKNELL, et al., (Eds.), <i>Tumour Angiogenesis</i> , Oxford University Press, New York (1997), Table of Contents, pp 5.	
	120	BLUM, et al., "Adriamycin: A New Anticancer Drug with Significant Clinical Activity," <i>Ann Intern Med</i> , (1974) 80(2):249-259.	
	121	BLUNT, et al., "Marine Natural Products," <i>Nat. Prod. Rep.</i> , (2003) 20:1-48.	
	122	BODART, et al., "Anthrax, MEK and Cancer," <i>Cell Cycle</i> , (2002) 1:10-15.	
	123	BRADLEY, et al., "Identification of the Cellular Receptor for Anthrax Toxin," <i>Nature</i> , (2001) 414:225-229.	
	124	BROSIUS, et al., "Complete nucleotide sequence of a 16S ribosomal RNA gene from <i>Eschericia coli</i> ," <i>Biochemistry</i> , (1978) 75(10):4801-4805.	
	125	BULL, et al., "Search and Discovery Strategies for Biotechnology: the Paradigm Shift," <i>Microbiol. Mol. Biol. Rev.</i> , (2000) 64(3):573-606	
	126	CAREY, Francis, <i>Organic Chemistry</i> , 2nd ed., McGraw Hill, Inc., New York (1992), pp. 328-331.	
	127	CHAUHAN, et al., "A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies," <i>Blood</i> , (2004) 104(11):2405.	
	128	CHAUHAN, et al., "A Novel Orally Active Proteasome Inhibitor Induces Apoptosis in Multiple Myeloma Cells with Mechanisms Distinct from Bortezomib," <i>Cancer Cell</i> , (2005) 8:407-419.	
	129	CHAUHAN, et al., "A Novel Proteasome Inhibitor NPI-0052 as an Anticancer Therapy," <i>British Journal of Cancer</i> , (2006) 95(8):961-965.	
	130	CHENG, et al., "Arenaric Acid, a New Pentacyclic Polyether Produced by a Marine Bacterium (Actinomycetales)," <i>J. Nat. Prod.</i> , (1999) 62:605-607.	
	131	CHENG, et al., "Luisols A and B, New Aromatic Tetraols Produced by an Estuarine Marine Bacterium of the Genus <i>Streptomyces</i> (Actinomycetales)," <i>J. Nat. Prod.</i> , (1999) 62:608-610.	
	132	CIECHANOVER, et al., (Eds.) "The Ubiquitin-Proteasome Proteolytic System - From Classical Biochemistry to Human Diseases" by Baumeister et al., (2002) pp. 68-70.	
	133	CLAVEROL, et al., "Mapping and Structural Dissection of Human 20 S Proteasome Using Proteomic Approaches," <i>Mol Cell Proteomics</i> , (2002) 1:567-78.	

Examiner Signature

Date Considered

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

WEST223652834.1
328342-000349

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/561,711
	Filing Date	September 11, 2009
	First Named Inventor	William H. Fenical
	Art Unit	1626
(Multiple sheets used when necessary)	Examiner	Powers, Fiona
SHEET 7 OF 21	Attorney Docket No.	UCSD1530-5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	134	COLE, et al., "The Ribosomal Database Project (RDP-II): sequences and tools for high-throughput rRNA analysis," <i>Nucleic Acids Research</i> , (2005) 33: D294-D296.	
	135	COLQUHOUN, et al, "Rapid Characterization of Deep-Sea Actinomycetes for Biotechnology Screening Programmes", <i>Antonie Van Leeuwenhoek</i> , (2000) 77:359-367	
	136	COLQUHOUN, et al., "Novel Rhodococci and Other Mycolate Actinomycetes From the Deep Sea," <i>Antonie van Leeuwenhoek</i> , (1998) 74:27-40.	
	137	COLQUHOUN, et al., "Taxonomy and Biotransformation Activities of Some Deep-Sea Actinomycetes," <i>Extremophiles</i> , (1998) 2:269-277.	
	138	COREY et al., "The Structural Requirements for Inhibition of Proteasome Function by the Lactacystin-derived beta-lactone and Synthetic Analogs," <i>Tetrahedron</i> (1999) 55(11):3305-3316.	
	139	COREY, et al., "Total Synthesis of Lactacystin," <i>J. Am. Chem. Soc.</i> , (1992) 114(26):10677-10678.	
	140	COREY, et al., "An Efficient Total Synthesis of a New and Highly Active Analog of Lactacystin," <i>Tetrahedron Letters</i> , (1998) 39:7475-7478.	
	141	CRAGG, et al., "Chemical Diversity: A Function of Biodiversity," <i>Trends Pharmacol. Sci.</i> , (2002) 23:404-5.	
	142	CRANE, et al., "A Novel Enantioselective Synthetic Route to Omuralide Analogues with the Potential for Species Selectivity in Proteasome Inhibition," <i>Organic Letters</i> , (2001) 1395-1397.	
	143	CRUEGER, et al., (Eds.), <i>Biotechnology: A Textbook of Industrial Microbiology</i> , 2nd ed. (English Edition, Thomas D. Brock Ed.), Sinauer Associates Inc , Sunderland MA, (1990) Chapter 2:4-8.	
	144	CUSACK, et al., "Enhanced Chemosensitivity to CPT-11 with Proteasome Inhibitor PS-341: Implications for Systemic Nuclear Factor-kB Inhibition", <i>Cancer Res.</i> , (May 1, 2001) 61(9):3535-40.	
	145	CUSACK, et al., "NPI-0052 Enhances Tumoricidal Response to Conventional Cancer Therapy in a Colon Cancer Model," <i>Clin. Cancer Res.</i> , (2006) 22:6758-6764.	
	146	CUSACK, et al., "Oral proteasome inhibitor (NPI-0052) enhances sensitivity to combination Gemcitabine and Erbitux in a pancreatic cancer xenograft model," Nereus Pharmaceuticals, Inc., (April 19, 2005), abstract 4943 for presentation at the American Association of Cancer Research Annual Meeting held on April 19, 2005 in Orange County, CA, 1 page.	
	147	CUSACK, et al., "Rationale for the Treatment of Solid Tumors with the Proteasome Inhibitor Bortezomib," <i>Cancer Treat Rev.</i> , (2003) 29(suppl 1): 21-31.	
	148	DAVIDSON, Bradley S., "New Dimensions in Natural Products Research: Cultured Marine Microorganisms," <i>Current Opinion in Biotechnology</i> , (1995) 6:284-291.	
	149	DECKER, et al., "Inhibition of Caspase-3-mediated Poly (ADP-ribose) Polymerase (PARP) Apoptotic Cleavage by Human PARP Autoantibodies and Effect on Cells Undergoing Apoptosis," <i>J. Biol. Chem.</i> , (2000) 275(12):9043-9046.	
	150	DELONG, et al., "Environmental Diversity of Bacteria and Archaea," <i>Syst. Biol.</i> , (2001) 50(4):470-478.	

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
WEST\223652834.1 328342-000349	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/561,711
	Filing Date	September 11, 2009
	First Named Inventor	William H. Fenical
	Art Unit	1626
(Multiple sheets used when necessary)	Examiner	Powers, Fiona
SHEET 8 OF 21	Attorney Docket No.	UCSD1530-5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	151	Developmental Therapeutics Program - NCI/NIH, "DTP Human Tumor Cell Line Screen." Screening Services. DPI. 28 Sept. 2005 http://dtp.nci.nih.gov/branches/btb/ivclsp.html	
	152	Developmental Therapeutics Program - NCI/NIH, "Cell Lines in the in Vitro Screen", online: http://dtp.nci.nih.gov/docs/misc/common_files/cell_list/html , accessed 10/27/2009.	
	153	DICK, et al., "Mechanistic Studies on the Inactivation of the Proteasome by Lactacystin," <i>J. Biol. Chem.</i> , (1996) 271(13):7273-7276.	
	154	DING, et al., "Proteasome Inhibition Induces Reversible Impairments in Protein Synthesis," <i>The FASEB Journal</i> , (2006) 20:1055-1063.	
	155	DUESBERY, et al., "Proteolytic Inactivation of MAP-Kinase-Kinase by Anthrax Lethal Factor," <i>Science</i> , (1998) 280:734-737.	
	156	ELLIOTT, et al., "The Proteasome: A New Target for Novel Drug Therapies," <i>American Journal of Clinical Pathology</i> , (November 2001) 637-646.	
	157	ELLIOTT, et al., "Proteasome Inhibition: A New Anti-Inflammatory Strategy," <i>J. Mol. Med.</i> , (2003) 81:235-245.	
	158	ENDO, et al., "Total Synthesis of Salinosporamide A," <i>J. Am. Chem. Soc.</i> , (2005) 127(23): 8298-8299 and Supporting Information S1-S23.	
	159	ERBA, et al., "Mode of Action of Thiocoraline: A Natural Marine Compound With Anti-Tumor Activity," <i>British Journal of Cancer</i> , (1999) 88(7):971-980.	
	160	ESCUYER, et al., "Anthrax Protective Antigen Interacts with a Specific Receptor on the Surface of CHO-K1 Cells," <i>Infect. Immun.</i> , (1991) 59(10):3381-3386.	
	161	FAULKNER, D. John, "Marine Natural Products," <i>Nat. Prod. Rep.</i> , (2001) 18(1):1-49.	
	162	FELING, et al., "Salinosporamide A: A Highly Cytotoxic Proteasome Inhibitor from a Novel Microbial Source, a Marine Bacterium of the New Genus Salinospira," <i>Angew. Chem. Int. Ed.</i> , (2003) 42(3):355-357.	
	163	FENICAL, et al., "Discovery and Development of the Anticancer Agent Salinosporamide A (NPI-0052)," <i>Bioorganic & Med. Chem.</i> , (2009) 17:2175-2180.	
	164	FENICAL, et al., "Marine Microorganisms as a Biomedical Source: Are They Unculturable or Uncultured?" PowerPoint Presentation, Center for Marine Biotechnology and Biomedicine (02/24/2002)	
	165	FENICAL, et al., "Marine Microorganisms as a Developing Resource for Drug Discovery," <i>Pharmaceutical News</i> , (2002) 9:489-494	
	166	FENICAL, et al., "Salinospira, a Major New Marine Actinomycete Taxon for Drug Discovery," Powerpoint Presentation, Center for Marine Biotechnology and Biomedicine" (06/24/2001)	
	167	FENICAL, William, "Chemical Studies of Marine Bacteria: Developing a New Resource," <i>Chem. Rev.</i> , (1993) 93(5):1673-1683.	

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>WEST\223652834.1 328342-000349</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/561,711
	Filing Date	September 11, 2009
	First Named Inventor	William H. Fenical
	Art Unit	1626
(Multiple sheets used when necessary)	Examiner	Powers, Fiona
SHEET 9 OF 21	Attorney Docket No.	UCSD1530-5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	168	FENICAL, William, "New Pharmaceuticals From Marine Organisms," <i>Marine Biotechnology</i> , (1997) 15:339-341.	
	169	FENTEANY, et al., "Lactacystin, Proteasome Function, and Cell Fate," <i>J. Biol. Chem.</i> (1998) 273(15): 8545-8548.	
	170	FENTEANY, et al., "Inhibition of Proteasome Activities and Subunit-Specific Amino-Terminal Threonine modification by Lactacystin," <i>Science</i> , (1995) 268:726-731.	
	171	FERNANDEZ-CHIMENO, et al., "IB-96212, a Novel Cytotoxic Macrolide Produced by a Marine <i>Micromonospora</i> ," <i>Journal of Antibiotics</i> , (2000) 53(5):474-478.	
	172	FINGL, et al., "General Principals," <i>The Pharmaceutical Basis of Therapeutics</i> , 5th Ed., (GOODMAN et al. Eds., 1975), MacMillan Publishing Co. Inc., New York, Chapter 1:1-46.	
	173	FOLKMAN, Judah, "Angiogenesis-Dependent Diseases," <i>Seminars in Oncology</i> , (December, 2001) 28:536-542.	
	174	FOLKMAN, Judah, "Tumor Angiogenesis," <i>Adv Cancer Res.</i> , (1985) 43:175-203.	
	175	FUKUCHI, et al., "Direct proteasome inhibition by clasto-lactacystin β -lactone permits the detection of ubiquitinated p21 in ML-1 Cells," <i>Biochem. Biophys. Acta</i> , (1999) 1451:206-210.	
	176	GALE, et al., (Eds.), <i>The Molecular Basis of Antibiotic Action</i> , 2nd ed., John Wiley and Sons, London (1981) Table of Contents, pp 1-13.	
	177	GANTT, et al., "Proteasome Inhibitors Block Development of Plasmodium SPP", <i>Antimicrobial Agents and Chemotherapy</i> , (1998) 2731-2738.	
	178	GEIER, et al., "A Giant Protease with Potential to Substitute for Some Functions of the Proteasome," <i>Science</i> , (1999) 283:978-981.	
	179	GENNARO, A.R. (Ed.), <i>REMINGTON'S Pharmaceutical Sciences</i> , 17th Ed., Mack Publishing Co., Easton, PA, (1985), Table of Contents, pp 5.	
	180	GENNARO, A.R. (Ed.), <i>REMINGTON'S Pharmaceutical Sciences</i> , 18th Ed., Mack Publishing Co., Easton, PA (1990), Table of Contents, pp 5.	
	181	GIANNANGELI et al., "Effect of Modifications of the Alkylpiperazine Moiety of Trazodone on 5HT _{2A} and α_1 Receptor Binding Affinity," <i>J. Med. Chem.</i> , (1999) 42(3):336-45.	
	182	GIOVANNONI, Stephen, "Oceans of Bacteria," <i>Nature</i> , (July 29, 2004) 430:515-16.	
	183	GOLDBERG, et al., "Not Just Research Tools – Proteasome Inhibitors Offer Therapeutic Promise," <i>Natural Medicine</i> , (2002) 338-40.	
	184	GOLUB, et al., "Molecular Classification of Cancer; Class Discovery and Class Prediction by Gene Expression Monitoring", <i>Science</i> , (1999) 286:531-37.	
	185	GOODFELLOW, et al., "Actinomycetes in Biotechnology," <i>Search and Discovery of New Antibiotics</i> , Okami, et al., eds., Academic Press, San Diego, (1988) Chapter 2:33-67.	

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
WEST\223652834.1 328342-000349	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/561,711
	Filing Date	September 11, 2009
	First Named Inventor	William H. Fenical
	Art Unit	1626
(Multiple sheets used when necessary)	Examiner	Powers, Fiona
SHEET 10 OF 21	Attorney Docket No.	UCSD1530-5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	186	GOODFELLOW, et al., "Actinomycetes in Marine Sediments," <i>Biological Biochemical and Biomedical Aspects of Actinomycetes</i> , Ortiz-Ortiz, et al., eds., Academic Press, Inc., Orlando (1984) 453-72.	
	187	GOODFELLOW, et al., "Ecology of Actinomycetes," <i>Ann. Rev. Microbiol.</i> , (1983) 37:189-216.	
	188	GOODFELLOW, et al., "Search and Discovery of Industrially Significant Actinomycetes," <i>Microbial Products: New Approaches, Society for General Microbiology Symposium</i> , (1989) 44:343-83.	
	189	GRANT, et al., "Intracellular Mechanisms Involved in Basement Membrane Induced Blood Vessel Differentiation In Vitro," <i>In Vitro Cell Dev. Biol.</i> , (1991) 27A:327-36.	
	190	GROSIO, et al., "Angiogenesis Inhibition by the Novel VEGF Receptor Tyrosine Kinase Inhibitor; PTK787/ZK222584, Causes Significant Anti-Arthritic Effects in Models of Rheumatoid Arthritis," <i>Inflamm Res</i> , (2004) 53: 133-142.	
	191	HANNA, et al., "On the Role of Macrophages in Anthrax," <i>Proc. Natl. Acad. Sci. USA</i> , (1993) 90:10198-10201.	
	192	HARDT, et al., "Neomarinone, and New Cytotoxic Marinone Derivatives, Produced by a Marine Filamentous Bacterium (Actinomycetales)," <i>Tetrahedron Letters</i> , (2000) 41(13):2073-2076.	
	193	HARKER, et al., "Multidrug Resistance in Mitoxantrone-Selected HL-60 Leukemia Cells in the Absence of P-Glycoprotein Overexpression," <i>Cancer Res.</i> , (1989) 49(16): 4542-4549.	
	194	HE, et al., "Lomaiviticins A and B, Potent Antitumor Antibiotics from <i>Micromonospora lomaivitiensis</i> ," <i>J. Am. Chem. Soc.</i> , (2001) 123(22):5362-5363.	
	195	HELMKE, et al., "Rhodococcus Marinonascens sp. nov.: An Actinomycete From the Sea," <i>International J. of Systematic Bacteriology</i> , (April, 1984) 34(2):127-138.	
	196	HIDESHIMA, et al., "NF- κ B as a Therapeutic Target in Multiple Myeloma," <i>J. Biol. Chem.</i> , (2002) 277(19):16639-16647.	
	197	HIGUCHI, et al., "Pro-Drugs as Novel Delivery Systems," Vol. 14, A.C.S. Symposium Series <i>American Chemical Society</i> , Atlantic City, NJ., September 10, 1974, (1975) Table of Contents, pp 3.	
	198	HOGAN, et al., "Proteasome Inhibition by a Totally Synthetic β -Lactam Related to Salinosporamide A and Omuralide," <i>J. Am. Chem. Soc.</i> , (2005) 127(44):15386-15387.	
	199	HOPWOOD, et al., "Genetic Manipulation of <i>Streptomyces</i> Polyketide Synthase Genes for Novel Secondary Metabolite Production," <i>FEMS Microbiology Reviews</i> , (1995) 16:233-234.	
	200	HORAN, Ann C., "Aerobic Actinomycetes: A Continuing Source of Novel Natural Products," <i>The Discovery of Natural Products with Therapeutic Potential (Biotechnology)</i> , Vincent P. Gullo (Ed.), Butterworth-Heinemann, Boston (1994) Chapter 1: 1-30.	
	201	HULL, et al., "Antiangiogenic Agents Are Effective Inhibitors of Endometriosis," <i>J. Clinical Endocrinology Metabolism</i> , (2003) 88:2889-2899.	
	202	JENSEN, et al., "Distribution of Actinomycetes in Near-Shore Tropical Marine Sediments," <i>Applied and Environmental Microbiology</i> , (April, 1991) 57(4):1102-1108.	

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>WEST\223652834.1 328342-000349</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/561,711
	Filing Date	September 11, 2009
	First Named Inventor	William H. Fenical
	Art Unit	1626
(Multiple sheets used when necessary)	Examiner	Powers, Fiona
SHEET 11 OF 21	Attorney Docket No.	UCSD1530-5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	203	JENSEN, et al., "Strategies for the Discovery of Secondary Metabolites from Marine Bacteria: Ecological Perspectives," <i>Annu. Rev. Microbiology</i> , (1994) 48:559-584.	
	204	JENSEN, et al., "The Relative Abundance and Seawater Requirements of Gram-Positive Bacteria in Near-Shore Tropical Marine Samples," <i>Microbial Ecology</i> , (1995) 29(3):249-257.	
	205	JENSEN, et al., "Marine Microorganisms and Drug Discovery: Current Status and Future Potential," <i>Drugs from the Sea</i> , Nobuhiro Fusetani Ed., <i>Krager</i> , Basel Switzerland (2000) 6-29.	
	206	JIANG, et al., "Antinoflavoside, A Novel Flavonoid-Like Glycoside Produced by a Marine Bacterium of the Genus <i>Streptomyces</i> ," <i>Tetrahedron Letters</i> , (1997) 38(29):5065-5068.	
	207	JOHNSON et al., "Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials", <i>British J Cancer</i> , (2001) 84(11): 1424-1431.	
	208	JOSEPH, et al., "Laboratory Cultivation of Widespread and Previously Uncultured Soil Bacteria," <i>Applied and Environmental Microbiology</i> , (2003) 69(12):7210-7215.	
	209	JOSHI, A., "Microparticulates for Ophthalmic Drug Delivery," <i>J. Ocul. Pharmacol.</i> , (1994) 10:29-45.	
	210	KALNS, et al., "Delayed Treatment With Doxycycline Has Limited Effect on Anthrax Infection in BLK57/B6 Mice," <i>Biochem. Biophys. Res. Commun.</i> , (2002) 297:506-509.	
	211	KALNS, et al., "TNF Receptor 1, IL-1 Receptor, and iNOS Genetic Knockout Mice Are Not Protected from Anthrax Infection," <i>Biochem. Biophys. Res. Commun.</i> , (2002) 292:41-44.	
	212	KERR, et al., "Marine Natural Products as Therapeutic Agents", Exp. Opinion on Therapeutic Patents, (1999) 9(9):1207-1222.	
	213	KHANBOLOOKI, et al., "Novel NFkB inhibitors NPI-1342/NPI-1387 and proteasome inhibitor NPI-0052 overcome resistance of pancreatic carcinoma to rhTRAIL," Nereus Pharmaceuticals, Inc., (April 2, 2006), abstract 780 for presentation at the American Association of Cancer Research Annual Meeting held on April 2, 2006 in Washington, D.C., 1 page.	
	214	KIM, et al., "Sensitizing Anthrax Lethal Toxin-Resistant Macrophages to Lethal Toxin-Induced Killing by Tumor Necrosis Factor," <i>J. Biol. Chem.</i> , (2003) 278:7413-7421.	
	215	KING, et al., "How Proteolysis Drives the Cell Cycle," <i>Science</i> , (1996) 274:1652-1659.	
	216	KISSELEV, et al., "Proteasome Inhibitors: From Research Tools to Drug Candidates," <i>Chem. Biol.</i> , (2001) 8:739-758.	
	217	KISSELEV et al., "Importance of the Different Proteolytic Sites of the Proteasome and the Efficacy of Inhibitors Varies with the Protein Substrate," <i>J Bio Chem.</i> , (March 2006) 281(13): 8582-8590.	
	218	KOCH, et al., "16S Ribosomal DNA Analysis of The Genera <i>Micromonospora</i> , <i>Actinoplanes</i> , <i>Catellatospora</i> , <i>Catenuloplanes</i> , <i>Dactylosporangium</i> , and <i>Pillimelia</i> and Emendation of the Family <i>Micromonosporaceae</i> ," <i>Intl Journal of Systematic Bacteriology</i> , (July, 1996) 46(3):765-768.	
	219	KOZLOWSKI, et al., "Lactacystin Inhibits Cathepsin A Activity in Melanoma Cell Lines," <i>Tumor Biol.</i> , (2001) 22:211-215.	

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
WEST223652834.1 328342-000349	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/561,711
	Filing Date	September 11, 2009
	First Named Inventor	William H. Fenical
	Art Unit	1626
(Multiple sheets used when necessary)	Examiner	Powers, Fiona
SHEET 12 OF 21	Attorney Docket No.	UCSD1530-5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	220	LACY, et al., "Mapping the Anthrax Protective Antigen Binding Site on the Lethal and Edema Factors," <i>J. Biol. Chem.</i> , (2002) 277:3006-3010.	
	221	LAM, et al., "Isolation of a Bromo Analog of Rebeccamycin From <i>Saccharothrix Aerocolonigenes</i> ," <i>J. Antibiotics</i> , (September, 1991) 44(9):934-939.	
	222	LAM, et al., "Production, Isolation and Structure Determination of Novel Fluoroindolocarbazoles from <i>Saccharothrix aerocolonigenes</i> ATCC 39243," <i>J. Antibiotics</i> , (2001) 54(1):1-9.	
	223	LAWLEY, et al., "Induction of Morphologic Differentiation of Endothelial Cells in Culture," <i>J. Investigative Dermatology</i> , (August, 1989) 93(2 Supplement):59S-61S.	
	224	LENZ, et al., "Clinical Update: Proteasome Inhibitors in Solid Tumors", <i>Cancer Treatment Reviews</i> , (2003) 29 (1 Supplement):41-48.	
	225	LIGHTCAP, et al., "Proteasome Inhibition Measurements Clinical Application," <i>Clin. Chem.</i> , (2000) 46(5):673-683.	
	226	LIN, et al., "Cytotoxic Effects of Anthrax Lethal Toxin on Macrophage-Like Cell Line J774A.1," <i>Curr. Microbiol.</i> , (1996) 33:224-227.	
	227	LIU, et al., "Angiogenesis Inhibitors May Regulate Adiposity," <i>Nutr. Rev.</i> , (2003) 61:384-387.	
	228	LIU, et al., "Precursor Supply for Polyketide Biosynthesis: The Role of Crotonyl-CoA Reductase," <i>Metab. Eng.</i> , (2001) 3:40-48	
	229	MACHERLA, et al., "Structure-Activity Relationship Studies of Salinosporamide A (NPI-0052), a Novel Marine Derived Proteasome Inhibitor," <i>J. Med. Chem.</i> , (2005) 48(11): 3684-3687.	
	230	MANAM et al., Leaving Groups Prolong the Duration of 20S Proteasome Inhibition and Enhance the Potency of Salinosporamide, <i>J Med Chem.</i> , (October 2008) 51(21): 6711-6724.	
	231	MANCHAND, et al., "Syntheses of the Anti-AIDS Drug 2',3'-Dideoxycytidine from Cytidine," <i>J. Org. Chem.</i> , (1992) 57:3473-3478.	
	232	MAYER, et al., "Efficacy of a Novel Hydrogel Formulation in Human Volunteers," <i>Ophthalmologica</i> , (1996) 210(2):101-103.	
	233	MAYER, et al., "Marine Pharmacology in 1999: Antitumor and Cytotoxic Compounds," <i>Anticancer Res.</i> , (2001) 21:2489-2500.	
	234	McMURRY, John, <i>Organic Chemistry</i> , 5th ed., Brooks/Cole, Pacific Grove, CA. (2000), Chapter 11.5, pp. 398-408.	
	235	MENG, et al., "Eponemycin Exerts its Antitumor Effect Through the Inhibition of Proteasome Function," <i>Cancer Res.</i> , (1999), 59(12):2798-2801.	
	236	MENG, et al., "Epoxomicin, a Potent and Selective Proteasome Inhibitor, Exhibits In Vivo Anti-Inflammatory Activity," <i>Proc. Natl. Acad. Sci. USA</i> , (August, 1999) 96:10403-10408.	
	237	MERRIAM-WEBSTER Online Dictionary, "Heteroatom", 2010, Merriam-Webster Online, accessed 16 June 2010, http://merriam-webster.com/dictionary/heteroatom .	

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>WEST\223652834.1 328342-000349</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/561,711
	Filing Date	September 11, 2009
	First Named Inventor	William H. Fenical
	Art Unit	1626
(Multiple sheets used when necessary)	Examiner	Powers, Fiona
SHEET 13 OF 21	Attorney Docket No.	UCSD1530-5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	238	MIN, et al., "Urokinase Receptor Antagonists Inhibit Angiogenesis and Primary Tumor Growth in Syngeneic Mice," <i>Cancer Res.</i> , (May 15, 1996) 56(10):2428-2433.	
	239	MINCER, et al., "Widespread and Persistent Populations of a Major New Marine Actinomycete Taxon in Ocean Sediments," <i>Applied and Environmental Microbiology</i> , (October, 2002) 68(10):5005-5011.	
	240	MOGRIDGE, et al., "Stoichiometry of Anthrax Toxin Complexes," <i>Biochemistry</i> , (2002) 41:1079-1082.	
	241	MOMOSE, et al., "2(3H)-and 2(5H)-Furanones. VII. Chirality Transfer on the Tetrionic Acid Templates," <i>Heterocycles</i> , (1999) 51(6):1321-1343.	
	242	MOORE, B.S., "Biosynthesis of Marine Natural Products: Microorganisms and Macroalgae," <i>Nat. Prod. Rep.</i> , (1999) 16(6):653-674.	
	243	MORAN, et al., "Evidence for Indigenous Streptomyces Populations in Marine Environment Determined with a 16S rRNA Probe," <i>Applied and Environmental Microbiology</i> , (October, 1995) 61(10):3695-3700.	
	244	MORDENTI, et al., "Intraculular Pharmacokinetics and Safety of a Humanized Monoclonal Antibody in Rabbits after Intravitreal Administration of a Solution or a PLGA Microsphere Formulation," <i>Toxicol. Sci.</i> , (1999) 52(1):101-106.	
	245	MOUSA, et al., "Angiogenesis Inhibitors: Current & Future Directions," <i>Current Pharmaceutical Design</i> , (2004) 10:1-9.	
	246	MULHOLLAND et al., "A Concise Total Synthesis of Salinosporamide A," <i>Org. Biomol. Chem.</i> , (2006) 4: 2845-6.	
	247	MURRAY, J. Clifford (Ed.), <i>Angiogenesis Protocols (Methods in Molecular Medicine)</i> , Humana Press, Totowa, NJ. (2001) Table of Contents, p. 4.	
	248	MUTOMBA, et al., "Inhibition of Proteasome Activity Blocks Cell Cycle Progression at Specific Phase Boundaries in African Trypanosomes", <i>Mol. Biochem. Parasitology</i> , (1997) 90:491-504.	
	249	NCBI website, sequence for AB242910, http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=124300751 , 2 pages, downloaded 2/15/07, 2 pages.	
	250	NCBI website, sequence for EF105548, http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=118640518 , 2 pages, downloaded 2/15/07, 2 pages.	
	251	NCBI website, Sequence for EF191171, http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=124014014 , 2 Pages, downloaded 2/15/07, 2 pages.	
	252	NESTERNEKO, et al., " <i>Rhodococcus luteus</i> nom. nov., and <i>Rhodococcus maris</i> nom. nov.", <i>Int'l Journal of Systematic Bacteriology</i> , (January, 1982) 32(1):1-14.	
	253	NEWTON. "Il fondo agli oceani potenti antibiotici e anticancro." www.newton.rcs.it/PrimoPiano/News/2003/02_Febbraio/03/Antibiotico.html . (February 2, 2003) 1 page.	✓
	254	NICHOLSON, D.W., "ICE/CED 3-Like Proteases as Therapeutic Targets for the Control of Inappropriate Apoptosis," <i>Nat. Biotechnology</i> , (1996) 14:297-301.	

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>WEST\223652834.1 328342-000349</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/561,711
	Filing Date	September 11, 2009
	First Named Inventor	William H. Fenical
	Art Unit	1626
(Multiple sheets used when necessary)	Examiner	Powers, Fiona
SHEET 14 OF 21	Attorney Docket No.	UCSD1530-5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	255	NICOLAUS B.J. R. "Symbiotic Approach to Drug Design," <i>Decision Making in Drug Research</i> , (1983) 173-186.	
	256	NICOSIA, et al., "Growth of Microvessels in Serum-Free Matrix Culture of Rat Aorta: A Quantitative Assay of Angiogenesis <i>In Vitro</i> ," <i>Laboratory Investigation</i> , (July 1990) 63(1):115-122.	
	257	NOLAN, et al., "Isolation and Screening of Actinomycetes," <i>Actinomycetes in Biotechnology</i> , (1988) Chapter 1:1-32.	
	258	O'DONNELL, Anthony G., "Recognition of Novel Actinomycetes," <i>Actinomycetes in Biotechnology</i> , Academic Press, (1988) Chapter 3:69-88.	
	259	OIKAWA, et al., "Angiogenic Factor of a Rat Mammary Tumor Cell Line (RMT-1) (I). Secretion of Two Distinct Angiogenic Factors into Serum-Free Conditioned Medium by RMT-1 Cells," <i>Cancer Letters</i> , (1991) 59:57-66.	
	260	OKAMI, Y., "The Search for Bioactive Metabolites from Marine Bacteria," <i>J. Marine Biotechnology</i> , (1993) 1: 59-65.	
	261	OMURA, et al., "Lactacystin, A Novel Microbial Metabolite, Induces Neuritogenesis of Neuroblastoma Cells," <i>J. Antibiotics</i> , (1991) 44(1): 113-116.	
	262	O'NEIL et al. eds., "The Merck Index," 13th Ed. 2001, Merck Research Laboratories, Whitehouse Station N.J., pp. THER-5 - THER-7.	
	263	ONLINE URL: http://aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=244 ; pp 1-2.	
	264	ONLINE URL: http://web.archive.org/web/20060117081111/hivhep.tempdomainname.com/hiv_and_aids/norvir_effects... 11/22/2010. 1 page.	
	265	ONLINE URL: http://en.wikipedia.org/wiki/Myeloma ; pp 1-8.	
	266	ONLINE URL: http://en.wikipedia.org/wiki/Sarcoma ; pp 1-2.	
	267	ONLINE www.netdoctor.co.uk "Isoniazid: Treatment of Tuberculosis", [accessed on April 8, 2008] pp. 1-2.	
	268	OSTROWSKA, et al., "Lactacystin, A Specific Inhibitor of the Proteasome, Inhibits Human Platelet Lysosomal Cathepsin A-like Enzyme," <i>Biochem. Biophys. Res. Commun.</i> , (1997) 234:729-732.	
	269	OSTROWSKA, et al., "Separation of Cathepsin A-like Enzyme and the Proteasome: Evidence that Lactacystin/ β -Lactone is not a Specific Inhibitor of the Proteasome," <i>Int. J. Biochem. Cell Biol.</i> , (2000) 32:747-757.	
	270	OTOGURO, et al., "An integrated method for the enrichment and selective isolation of <i>Actinokineospora</i> spp. in soil and plant litter," <i>J. Appl. Microbiol.</i> , (2001) 92:118-130.	
	271	PAGANO, et al., "Role of the Ubiquitin-Proteasome Pathway in Regulating Abundance of the Cyclin-Dependent Kinase Inhibitor p27," <i>Science</i> , (1995) 269(5224):682-685.	

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>WEST\223652834.1 328342-000349</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/561,711
	Filing Date	September 11, 2009
	First Named Inventor	William H. Fenical
	Art Unit	1626
(Multiple sheets used when necessary)	Examiner	Powers, Fiona
SHEET 15 OF 21	Attorney Docket No.	UCSD1530-5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	272	PAGE, Roderic D.M., "TreeView: An Application to Display Phylogenetic Trees on Personal Computers," <i>Computer Applications in the Biosciences</i> , (1996) 12:357-358.	
	273	PAINTER, Robert B., "Inhibition of DNA Replicon Initiation by 4-Nitroquinoline 1-Oxide, Adriamycin, and Ethyleneimine," <i>Cancer Res.</i> , (1978) 38(12):4445-4449.	
	274	PALAYOOR, et al., "Constitutive Activation of I κ B Kinase α and NF- κ B in Prostate Cancer Cells is Inhibited by Ibuprofen," <i>Oncogene</i> , (1999) 18:7389-7394.	
	275	PECKHAM et al. (Eds.), "The Oxford Textbook of Oncology," <i>Oxford University Press</i> , Oxford (1995) Volume 1:447-453.	
	276	PIETERS et al., "Microbiology: Chemical Warfare and Mycobacterial Defense", <i>Science</i> , (12/2003) 302:1900-1902.	
	277	PLUNKETT, et al., "Methods in Laboratory Investigation: An <i>In Vivo</i> Quantitative Angiogenesis Model Using Tumor Cells Entrapped in Alginate," <i>Laboratory Investigation</i> , (April, 1990) 62(4):510-517.	
	278	PRUDHOMME et al., "Marine Actinomycetes: A New Source of Compounds against the Human Malaria Parasite," <i>Plos One</i> , (2008) 3(6): 1-8.	
	279	QURESHI, et al., "The Proteasome as a Lipopolysaccharide-Binding Protein in Macrophages: Differential Effects of Proteasome Inhibition on Lipopolysaccharide-Induced Signaling Events," <i>J. Immunol.</i> , (2003) 171(3):1515-1525.	
	280	RAPPE, et al., "Cultivation of the Ubiquitous SAR11 Marine Bacterioplankton Clade," <i>Nature</i> , (August 8, 2002) 418:630-633.	
	281	REDDY, et al., "A Simple Stereocontrolled Synthesis of Salinosporamide A," <i>J. Am. Chem. Soc.</i> , (2004) 126(20):6230-6231.	
	282	REED et al., "Salinosporamides D-J from the Marine Actinomycete <i>Salinispora tropica</i> , Bromosolinosporamide, and Thioester Derivatives Are Potent Inhibitors of the 20S Proteasome", <i>J Nat Prod.</i> , (2007) 70: 269-276.	
	283	RIVA, S., "Biocatalytic Modification of Natural Products," <i>Curr. Opin. Chem. Biol.</i> , (2001) 5:106-111.	
	284	ROCCARO, et al., "Dual Targeting of the Proteasome Regulates Survival and Homing in Waldenstrom Macroglobulinemia." <i>Blood</i> , (March 2008) 111(9): 4752-4763.	
	285	ROCHE, Edward B. (Ed.), "Bioreversible Carriers in Drug Design: Theory and Application," Pergamon Press , Elmsford, NY (1987), pp. 14-21.	
	286	ROCKWELL, et al., "Proteasome Inhibition in Neuronal Cells Induces a Proinflammatory Response Manifested by Upregulation of Cyclooxygenase-2, Its Accumulation as Ubiquitin Conjugates, and Production of the Prostaglandin PGE ₂ ," <i>Arch. Biochem. and Biophysics</i> , (2000) 374(2):325-333.	
	287	ROMERO, et al., "Thiocoraline, a New Depsipeptide with Antitumor Activity Produced by a Marine <i>Micromonospora</i> ," <i>J. Antibiotics</i> , (1997) 50(9):734-737.	
	288	RUBANYI, Gabor M., "Angiogenesis in Health and Disease: Basic Mechanisms and Clinical Applications", <i>Marcel Dekker</i> , New York, NY (1999) pp 6 Content Pages Only.	

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
<p>WEST\223652834.1 328342-000349</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/561,711	
	Filing Date	September 11, 2009	
	First Named Inventor	William H. Fenical	
	Art Unit	1626	
(Multiple sheets used when necessary)		Examiner	Powers, Fiona
SHEET 16 OF 21		Attorney Docket No.	UCSD1530-5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	289	RUIZ, et al., "The Proteasome Inhibitor NPI-0052 is a More Effective Inducer of Apoptosis than Bortezomib in Lymphocytes from Patients with Chronic Lymphocytic Leukemia," <i>Mol. Cancer Ther.</i> , (2006) 5(7): 1836-1843.	
	290	SAPI, et al., "Simple and Condensed β -Lactam. Part 32. Base- and Acid-Catalyzed Ring Expansions of 3-Substituted 4-Acetylazetidin-2-ones and Related Compounds". <i>Collect. Czech. Chem. Commun.</i> (1999) 64(2):190-202.	
	291	SARAVANAN, et al., "A Short, Stereocontrolled, and Practical Synthesis of α -Methylomuralide, a Potent Inhibitor of Proteasome Function," <i>J. Org. Chem.</i> , (2003) 68(7):2760-2764.	
	292	SAUSVILLE et al., "Contributions of human tumor xenografts to anticancer drug development", <i>Cancer Res.</i> (2006) 66(7): 3351-3354.	
	293	SCHIEWE, H. (Reprint) HAUSTEDT, et al., "Rational approaches to natural-product-based drug design", <i>Curr Opin Drug Disc Devel.</i> (2006) 9(4):445-462.	
	294	SCHNAPER, et al., "Plasminogen Activators Augment Endothelial Cell Organization In Vitro by Two Distinct Pathways," <i>J. Cell. Physiol.</i> , (1995) 165:107-118.	
	295	SHADOMY, et al., "Antimycotic and Antirickettsial," <i>Antibiotics, Chemotherapeutics, and Antibacterial Agents for Disease Control</i> , Martin Grayson (Ed.) <i>John Wiley and Sons</i> , New York (1982) 371-395.	
	296	SHAH, et al., "Early Clinical Experience With the Novel Proteasome Inhibitor PS-519," <i>J. Clin. Pharmacol.</i> , (2002) 54:269-276.	
	297	SHEDDEN, et al., "Efficacy and Tolerability of Timolol Maleate Ophthalmic Gel-Forming Solution Versus Timolol Ophthalmic Solution in Adults with Open-Angle Glaucoma or Ocular Hypertension: A Six-Month, Double Masked, Multicenter Study," <i>Clin. Ther.</i> , (2001) 23(3):440-450.	
	298	SHIMADA, et al., "Contributions of Mitogen-Activated Protein Kinase and Nuclear Factor Kappa B to N-(4-hydroxyphenyl) Retinamide-Induced Apoptosis in Prostate Cancer Cells," <i>Molecular Carcinogenesis</i> , (2002) 35(3):127-137.	
	299	SHOEMAKER, R., "The NCI60 Human Tumour Cell Line Anticancer Drug Screen," <i>Nature Reviews Cancer</i> , (2006) 6:813-823.	
	300	SILVA-JARDIM, et al., "The <i>Leishmania Chagasi</i> Proteasome: Role in Promastigotes Growth and Amastigotes Survival within Murine Macrophages", <i>Acta Tropica</i> , (2004) 91:121-130.	
	301	SILVERMAN, Richard B., <i>The Organic Chemistry of Drug Design and Drug Action</i> , Academic Press , San Diego, (1992) 19-21.	
	302	STACH, et al., "New Primers for the Class <i>Actinobacteria</i> : Application to Marine and Terrestrial Environments," <i>Environmental Microbiology</i> , (2003) 5(10):828-841.	
	303	STACH, et al., "Statistical Approaches for Estimating Actinobacterial Diversity in Marine Sediments," <i>Appl. Environ. Microbiol.</i> , (October, 2003) 69(10):6189-6200.	
	304	STACKEBRANDT, et al., "Proposal for a New Hierarchic Classification Systems, <i>Actinobacteria</i> classis Nov.," <i>Int. J. of Syst. Bacteriol.</i> , (Apr, 1997) 47(2):479-491.	
	305	STACKEBRANDT, et al., "Taxonomic Note: A Place for DNA-DNA Reassociation and 16S rRNA Sequence Analysis in the Present Species Definition in Bacteriology," <i>Int. J. of Syst. Bacteriol.</i> , (Oct, 1994) 44(4):846-849.	

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>WEST223652834.1 328342-000349</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/561,711
	Filing Date	September 11, 2009
	First Named Inventor	William H. Fenical
	Art Unit	1626
(Multiple sheets used when necessary)	Examiner	Powers, Fiona
SHEET 17 OF 21	Attorney Docket No.	UCSD1530-5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	306	STADLER et al., "Cinnabaramides A-G: Analogues of Lactacystin and Salinosporamide from a Terrestrial Streptomyces," <i>J. Nat. Prod.</i> (February 2007) 70(2):246-252.	
	307	STANFORD, et al., "Bortezomib Treatment for Multiple Myeloma," <i>Ann. Pharmacother.</i> , (2003) 37:1825-1830.	
	308	STELLA et al., (Ed.), "Prodrugs: Challenges and Rewards, Part 1", American Association of Pharma. Scientists (2007), p. 24.	
	309	STREITWIESER et al., <i>Introduction to Organic Chemistry</i> , 2nd ed., Macmillan Publishing Co. Inc., New York, NY (1981) pp. 169-171.	
	310	SUNWOO, et al., "Novel Proteasome Inhibitor PS-341 Inhibits Activation of Nuclear Factor-kB, Cell Survival, Tumor Growth, and Angiogenesis in Squamous Cell Carcinoma," <i>Clin. Cancer Res.</i> , (2001) 7:1419-1428.	
	311	SUZUKI, et al., "Chemosensitization of Drug and Rituximab-Resistant Daudi B-NHL Clones to Drug-Induced Apoptosis by the Proteasome Inhibitor NPI-0052," <i>Blood</i> , (2005) 106:1521 abstract.	
	312	TABUCHI, et al., "Application of 'Proteasome Tolerance' to Therapies for Neurodegenerative Disease," <i>Alzheimer's and Dementia</i> , (2006) 2(3) (1 Supplement):S628.	
	313	TAKEUCHI, et al., "Trogilozone Induces G1 Arrest by p27 Induction That Is Mediated by Inhibition of Proteasome in Human Gastric Cancer Cells," <i>Jpn. J. Cancer Res.</i> , (2002) 93:774-782.	
	314	TANG, et al., "Cloning and Heterologous Expression of the Epithelial Gene Cluster," <i>Science</i> , (January 28, 2000) 287:640-642.	
	315	TANG, et al., "Proteasome Activity is Required For Anthrax Lethal Toxin to Kill Macrophages," <i>Infect. Immun.</i> , (1999) 67(6):3055-3060.	
	316	TAUCHI, et al., "Molecular Mechanisms of Resistance of Leukemia to Imatinib Mesylate," <i>Leukemia Research</i> , (May, 2004) 28:39-45.	
	317	THOMPSON, et al., "CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice," <i>Nucleic Acids Research</i> , (1994) 22(22):4673-4680.	
	318	U.S. Patent Application No. 12/329,518, Chen-Kiang, et al., entitled "Targeting CDK4 and CDK6 in Combination Cancer Therapy," filed December 5, 2008.	
	319	VERSALOVIC, et al., "Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes," <i>Nucleic Acids Research</i> , (1991) 19(24):6823-6831.	
	320	VITALE, et al., "Anthrax lethal factor cleaves the N-terminus of MAPKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages," <i>J. Applied Microbiology</i> , (1999) 87:288.	
	321	VITALE, et al., "Susceptibility of Mitogen-Activated Protein Kinase Kinase Family Members to Proteolysis by Anthrax Lethal Factor," <i>Biochem. J.</i> , (2000) 352:739-745.	
	322	VOSKOGLU-NOMIKOS, et al., "Clinical Predictive Value of the <i>in Vitro</i> Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models", <i>Clin Cancer Res.</i> , (2003) 9:4227-4239.	

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
WEST223652834.1 328342-000349	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/561,711
	Filing Date	September 11, 2009
	First Named Inventor	William H. Fenical
	Art Unit	1626
(Multiple sheets used when necessary)	Examiner	Powers, Fiona
SHEET 18 OF 21	Attorney Docket No.	UCSD1530-5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	323	WARD, Bess B., "How Many Species of Prokaryotes are There?" <i>Proc. Natl. Acad. Sci. USA</i> , (August 6, 2002) 99(16):10234-10236.	
	324	WATVE, et al., "How Many Antibiotics are Produced by the Genus <i>Streptomyces</i> ?" <i>Arch. Microbio.</i> , (2001) 176:386-390.	
	325	WEYLAND, H., "Actinomycetes in North Sea and Atlantic Ocean Sediments," <i>Nature</i> , (1969) 223:858.	
	326	WEYLAND, H., "Distribution of Actinomycetes on the Sea Floor," <i>Actinomycetes ZBL. Bakt. Suppl.</i> , (1981) 11:185-193.	
	327	WHEELIS, et al., "On the Nature of Global Classification," <i>Proc. Natl. Acad. Sci. USA</i> , (April, 1992) 89:2930-2934.	
	328	WILLIAMS et al., "New Cytotoxic Salinosporamides from the Marine Actinomycete <i>Salinispora Tropica</i> ," <i>J. Org. Chem.</i> , (2005) 70(16):6196-6203.	
	329	WOESE, Carl R., "Bacterial Evolution," <i>Microbiological Rev.</i> , (June, 1987) 51(2):221-271.	
	330	YEW, et al., "Proteasome Inhibition by Lactacystin in Primary Neuronal Cells Induces Both Potentially Neuroprotective and Pro-Apoptotic Transcriptional Responses: a Microarray Analysis," <i>J. Neurochem.</i> , (2005) 94(4):943-956.	
	331	ZAKS, A., "Industrial Biocatalysis," <i>Curr. Opin. Chem. Biol.</i> , (2001) 5:130-136.	
	332	ZHANG, et al., "Postischemic (6 Hour) Treatment with Recombinant Human Tissue Plaminogen Activator and Proteasome Inhibitor PS-519 Reduces Infarction in a Rat Model of Embolic Focal Cerebral Ischemia," <i>Stroke</i> , (2001) 2926-2931.	
	333	ZHENG, et al., "Detection of Antitumor and Antimicrobial Activities in Marine Organism Associated Actinomycetes Isolated From the Taiwan Strait, China," <i>FEMS Microbiology Letters</i> , (2000) 188:87-91.	
	334	International Search Report and Written Opinion dated July 12, 2006 in International Application No. PCT/US2005/044091, International Filing Date: 12/02/2005.	
	335	International Preliminary Report on Patentability dated June 14, 2007 in International Application No. PCT/US2005/044091, International Filing Date: 12/02/2005	
	336	International Search Report and Written Opinion (corrected version) dated July 8, 2005 in International Application No. PCT/US2004/019543, International Filing Date: 06/18/2004.	
	337	International Preliminary Report on Patentability dated January 3, 2006 in International Application No. PCT/US2004/019543, International Filing Date: 06/18/2004	
	338	International Search Report and Written Opinion dated November 29, 2004 in International Application No. PCT/US2004/019453, International Filing Date: 06/18/2004.	
	339	International Preliminary Report on Patentability dated March 14, 2005 in International Application No. PCT/US2004/19453, International Filing Date: 06/18/2004.	

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>WEST\223652834.1 328342-000349</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/561,711
	Filing Date	September 11, 2009
	First Named Inventor	William H. Fenical
	Art Unit	1626
(Multiple sheets used when necessary)	Examiner	Powers, Fiona
SHEET 19 OF 21	Attorney Docket No.	UCSD1530-5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	340	International Search Report and Written Opinion dated December 29, 2006 in International Application No. PCT/US2005/014846, International Filing Date: 04/29/2005.	
	341	International Preliminary Report on Patentability dated January 23, 2007 in International Application No. PCT/US2005/014846, International Filing Date: 04/29/2005.	
	342	International Search Report dated August 2, 2002 in International Application No. PCT/US01/043758, International Filing Date: 11/16/2001.	
	343	International Preliminary Report on Patentability dated August 24, 2004 in International Application No. PCT/US2001/043758, International Filing Date: 11/16/2001.	
	344	International Search Report and Written Opinion dated February 27, 2007 in International Application No. PCT/US06/016104, International Filing Date: 04/27/2006.	
	345	International Preliminary Report on Patentability dated October 30, 2007 in International Application No. PCT/US2006/016104, International Filing Date: 04/27/2006.	
	346	International Search Report and Written Opinion mailed January 29, 2009 for corresponding International Application No. PCT/US2008/062553 International Filing Date: 05/02/2008.	
	347	International Preliminary Report on Patentability dated November 19, 2009 in International Application No. PCT/US2008/062553, International Filing Date: 05/02/2008.	
	348	International Search Report and Written Opinion dated September 28, 2009 for International Application No. PCT/US2009/043644, International Filing Date: 05/12/2009.	
	349	International Preliminary Report on Patentability (Chapter II) dated August 6, 2010 for International Application No. PCT/US2009/043644, International Filing Date: 05/12/2009.	
	350	International Search Report and Written Opinion dated May 12, 2006 in International Application No. PCT/US2005/043668, International Filing Date: Dec. 2, 2005.	
	351	International Preliminary Report on Patentability dated June 14, 2007 in International Application No. PCT/US2005/043668, International Filing Date: 12/02/2005.	
	352	International Search Report and Written Opinion dated Nov. 15, 2005 in International Application No. PCT/US2005/012218, International Filing Date: April 11, 2005.	
	353	International Preliminary Report on Patentability dated October 11, 2006 in International Application No. PCT/US2005/012218, International Filing Date: April 11, 2005.	
	354	International Search Report and Written Opinion dated October 19, 2005 in International Application No. PCT/US2005/012113, International Filing Date: April 11, 2005.	
	355	International Preliminary Report on Patentability dated October 11, 2006 in International Application No. PCT/US2005/012113, International Filing Date: April 11, 2005.	
	356	International Search Report and Written Opinion dated Jan. 10, 2007 in International Application No. PCT/US2006/031314, International Filing Date: August 10, 2006.	
	357	International Preliminary Report on Patentability dated Feb. 12, 2008 in International Application No. PCT/US2006/031314, International Filing Date: August 10, 2006.	

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>WEST223652834.1 328342-000349</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/561,711
	Filing Date	September 11, 2009
	First Named Inventor	William H. Fenical
	Art Unit	1626
(Multiple sheets used when necessary)	Examiner	Powers, Fiona
SHEET 20 OF 21	Attorney Docket No.	UCSD1530-5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	358	International Search Report and Written Opinion dated August 3, 2007 in International Application No. PCT/US2006/035196, International Filing Date: Sept. 8, 2006.	
	359	International Preliminary Report on Patentability dated March 18, 2008 in International Application No. PCT/US2006/035196, International Filing Date: Sept. 8, 2006.	
	360	EFS File History of U.S. Serial No. 10/871,368, filed 03/03/2005.	Uploaded in 3 parts
	361	EFS File History of U.S. Serial No. 12/136,688, filed 06/10/2008 as of 01/20/2011.	Uploaded in 4 parts
	362	EFS File History of U.S. Serial No. 11/118,260, filed 04/29/2005.	Uploaded in 2 parts
	363	EFS File History of U.S. Serial No. 09/991,518, filed 11/16/2001.	Uploaded in 4 parts
	364	EFS File History of U.S. Serial No. 11/228,416, filed 09/15/2005.	
	365	EFS File History of U.S. Serial No. 11/841,588, filed 08/20/2007.	Uploaded in 2 parts
	366	EFS File History of U.S. Serial No. 11/966,787, filed 12/28/2007.	Uploaded in 2 parts
	367	EFS File History of U.S. Serial No. 11/966,801, filed 12/28/2007 as of 03/24/2011.	Uploaded in 3 parts
	368	EFS File History of U.S. Serial No. 10/600,854, filed 06/20/2003.	
	369	EFS File History of U.S. Serial No. 10/838,157, filed 04/30/2004.	
	370	EFS File History of U.S. Serial No. 11/147,622, filed 06/07/2005.	
	371	EFS File History of U.S. Serial No. 11/705,694, filed 02/12/2007.	Uploaded in 2 parts
	372	EFS File History of U.S. Serial No. 12/638,860, filed 12/15/2009 as of 05/16/2011.	
	373	EFS File History of U.S. Serial No. 11/412,476, filed 04/27/2006.	Uploaded in 2 parts
	374	EFS File History of U.S. Serial No. 11/865,704, filed 10/01/2007.	

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>WEST223652834.1 328342-000349</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/561,711
	Filing Date	September 11, 2009
	First Named Inventor	William H. Fenical
	Art Unit	1626
(Multiple sheets used when necessary)	Examiner	Powers, Fiona
SHEET 21 OF 21	Attorney Docket No.	UCSD1530-5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	375	EFS File History of U.S. Serial No. 11/453,374, filed 06/15/2006.	Uploaded in 2 parts
	376	EFS File History of U.S. Serial No. 12/114,449, filed 05/02/2008.	
	377	EFS File History of U.S. Serial No. 12/464,686, filed 05/12/09.	
	378	EFS File History of U.S. Serial No. 11/293,354, filed 12/02/2005.	
	379	EFS File History of U.S. Serial No. 12/183,007, filed 07/30/2008 as of 12/03/2010.	
	380	EFS File History of U.S. Serial No. 10/821,621, filed 04/09/2004.	
	381	EFS File History of U.S. Serial No. 11/539,648, filed 10/09/2006.	
	382	EFS File History of U.S. Serial No. 12/028,024, filed 02/08/2008.	
	383	EFS File History of U.S. Serial No. 11/224,589, filed 09/12/2005.	

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>WEST\223652834.1 328342-000349</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.